Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 11:55 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 25 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Cardio-Renal Syndrome Clear all

Conditions: Congestive Heart Failure, Renal Insufficiency
Interventions: furosemide and hypertonic saline solution, furosemide; Drug
Lead sponsor: Aspirus Heart and Vascular Institute-Research and Education; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Wausau, Wisconsin

Conditions: Chronic Kidney Disease, Cardiorenal Syndrome
Interventions: Doxycycline, Placebo (for Doxycycline); Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Cardiorenal Syndrome
Interventions: Dapagliflozin; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Congestive Heart Failure Exacerbation, Renal Insufficiency
Interventions: Natrecor, a recombinant form of B-type Natriuretic Peptide, made by Scios, Inc. vs. placebo; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Stanford, California

Conditions: Heart Failure; With Decompensation, Cardiorenal Syndrome, Cardio-Renal Syndrome, Heart Failure, Heart Failure，Congestive, Heart Failure, Systolic, Heart Failure, Diastolic
Interventions: Aortix System; Device
Lead sponsor: Procyrion; Industry
Eligibility: 21 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 14
States / cities: Los Angeles, California • San Francisco, California • Denver, Colorado + 11 more

Conditions: Heart Failure, Cardiorenal Disease, Renal Disfunction
Interventions: ANX-042, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 85 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Congestive Heart Failure, Renal Insufficiency
Interventions: Hypertonic saline, then oral sodium chloride, Normal saline, then oral placebo capsule; Drug
Lead sponsor: Barnes-Jewish Hospital; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Chronic Kidney Disease, Type 2 Diabetes
Interventions: Epic-Based Clinician Notification, Usual Care; Other
Lead sponsor: Baylor Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Dallas, Texas • Plano, Texas

Conditions: Heart Failure, Acute Kidney Injury
Interventions: Dapagliflozin 10mg Tab, Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 130 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: New Haven, Connecticut

Conditions: Cardiorenal Syndrome
Interventions: Nesiritide; Drug
Lead sponsor: Horng Chen; Other
Eligibility: 18 Years to 90 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Acute on Chronic Systolic Congestive Heart Failure, Cardiorenal Syndrome
Interventions: Selective Cytopheretic Device; Device
Lead sponsor: SeaStar Medical; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Heart Failure
Interventions: Not listed
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cardiorenal Syndrome (CRS)
Interventions: Candesartan, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Cardiorenal Syndrome
Interventions: JuxtaFlow System; Device
Lead sponsor: 3ive Labs; Industry
Eligibility: 22 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 4
States / cities: Gainesville, Florida • Cleveland, Ohio • San Antonio, Texas + 1 more

Conditions: Cardio-Renal Syndrome, Heart Failure, Chronic Kidney Diseases
Interventions: Fibroblast Growth Factor 23; Diagnostic Test
Lead sponsor: Coney Island Hospital, Brooklyn, NY; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Type 2 Diabetes Mellitus, Chronic Kidney Disease, Left Ventricular Diastolic Dysfunction
Interventions: BYDUREON, Placebo; Drug
Lead sponsor: Baylor Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Cardiorenal Syndrome
Interventions: Milrinone, Dobutamine; Drug
Lead sponsor: Maimonides Medical Center; Other
Eligibility: 18 Years to 95 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Hypertension (HTN), CKD - Chronic Kidney Disease, Cardio-Renal Syndrome, Food Insecurity, Type 2 Diabetes
Interventions: INTEGRATE-CHW, Usual Care; Behavioral
Lead sponsor: Florida International University; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2030
U.S. locations: 1
States / cities: Boynton Beach, Florida

Conditions: Heart Failure, Cardiorenal Syndrome, Cardio-Renal Syndrome, ADHF, Heart Failure, Systolic, Heart Failure, Diastolic, Heart Failure; With Decompensation, Heart Failure, Congestive
Interventions: Aortix System; Device
Lead sponsor: Procyrion; Industry
Eligibility: 21 Years and older
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 49
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Concord, California + 37 more

Conditions: Heart Failure
Interventions: Stepped pharmacologic care, Ultrafiltration; Drug · Device
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 188 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 8
States / cities: Phoenix, Arizona • Atlanta, Georgia • Minneapolis, Minnesota + 5 more

Conditions: Congestive Heart Failure, Cardiorenal Syndrome
Interventions: nesiritide, placebo; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Heart Failure, Chronic Systolic Heart Failure, Renal Failure, Cardiorenal Syndrome
Interventions: Selective Cytopheretic Device; Device
Lead sponsor: Lenar Yessayan; Other
Eligibility: 21 Years to 70 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Acute Decompensated Heart Failure
Interventions: Nesiritide, Nitroglycerin; Drug
Lead sponsor: Western University of Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Inglewood, California

Conditions: Cardiorenal Syndrome, Acute Decompensated Heart Failure
Interventions: Not listed
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

Safety and Efficacy of Low Dose Hypertonic Saline Solution and High Dose Furosemide for Congestive Heart Failure

A Trial of Doxycycline in Renal Disease

Sodium-Glucose Cotransporter-2 Inhibitor for Acute Cardiorenal Syndrome: A Feasibility Study

BNP for Cardio-Renal Decompensation Syndrome (BNP-CARDS)

The Aortix CRS Pilot Study

Safety and Efficacy of ANX-042 in Human Cardiorenal Syndrome

Concentrated Saline Infusions and Increased Dietary Sodium With Diuretics for Heart Failure With Kidney Dysfunction

RAndomized EHR-based Prescribing to Improve Disease-modifying Therapies for Cardio-Kidney-Metabolic Care (RAPID-CKM)

Sodium-Glucose Cotransporter-2 Inhibitor for Patients With Acute Cardiorenal Syndrome

Use of Nesiritide (BNP) in Kidney Function in Patients With Congestive Heart Failure (CHF) and Kidney Failure

Feasibility of the SCD in Cardiorenal Syndrome Patients Awaiting LVAD

Calcium, Phosphate, Renal Impairment and Coronary Artery Disease in the Cardio-renal Syndrome, The CAPRICORN-CRS Study

CR Aim #2 - AT1 Receptor Blockade & ACE Inhibition Effect on Humoral Function

Volume Optimization Incorporating Negative Pressure Diuresis in Heart Failure (VOID-HF)

Cardiorenal Risk Stratification Pilot Study

Extended Release Exenatide Versus Placebo In Diabetic Patients With Type 4 Cardiorenal Syndrome

Dobutamaine Versus Milrinone in Cardiorenal Syndrome

Community Health Worker Nutrition Self-Management Support for Cardio-Kidney-Metabolic Health

Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure

Effectiveness of Ultrafiltration in Treating People With Acute Decompensated Heart Failure and Cardiorenal Syndrome (The CARRESS Study)

Nesiritide and Renal Function After the Total Artificial Heart

SCD for CRS in Congestive Heart Failure (CHF) (No Left Ventricular Assist Device)

Assessment of Biomarkers and Cardiorenal Syndrome in Acute Decompensated Heart Failure With Vasodilator Therapy

Biomonitoring and Cardiorenal Syndrome in Heart Failure(BIONICS-HF) Trial